103 results
Page 2 of 6
8-K
EX-99.1
9olry5
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
8-K
EX-99.1
zyz4pu5xprmcatmv
10 Aug 22
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
5vm47zs8
20 Jul 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:01am
8-K
EX-99.1
07v31j
10 May 22
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:01pm
8-K
EX-99.1
g9y1q rq4dbbd3tda
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
5368oqg
30 Mar 22
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
5yj6 46t5zi
28 Mar 22
Soleno Therapeutics Announces Proposed Underwritten Public Offering
4:59pm
424B5
lu7 pu9lr2setvrla
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
shgfow8lhkb9c7
24 Jan 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:06am
8-K
EX-99.1
ut0mn48ripmdps0b4aln
10 Nov 21
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
4:16pm
424B5
rgyyc ewoiq0kxq4
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
gay84pw3qk sf
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
EX-99.2
f5asezaiz6ffk99ji8
15 Apr 21
Other Events
12:00am
8-K
EX-99.1
jwg6b8
8 Mar 21
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
4:01pm
8-K
EX-99.1
e1b5ic5v
3 Mar 21
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year
4:01pm